Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

How are patients transitioned from another basal insulin to Abasaglar® (insulin glargine)?

If transitioning from another basal insulin to Abasaglar, the recommended initial Abasaglar dose is based on the insulin therapy that is being discontinued.

UK_cFAQ_BIV049_TRANSITION_TABLE
UK_cFAQ_BIV049_TRANSITION_TABLE
en-GB

Transitioning from another basal insulin to Abasaglar therapy

Reductions in the Abasaglar dose when transitioning from certain insulins will lower the likelihood of hypoglycemia.1,2

Please find a transition table in Transitioning From Another Basal Insulin to Abasaglar Therapy.

Transitioning From Another Basal Insulin to Abasaglar Therapy1,2

If transitioning from…

To…

Then, the recommended initial dose of Abasaglar …

Example

Lantus

Abasaglar

is the same as the Lantus dose.

50 units of Lantus transitions to 50 units of Abasaglar

Toujeo

Abasaglar

is 80% of the Toujeo dose.

50 units of Toujeo transitions to 40 units of Abasaglar

twice-daily NPH insulin

once-daily Abasaglar

is 70%-80% of the total daily NPH insulin dosage.

25 units of NPH insulin every morning and 25 units of NPH insulin every evening, for a daily total of 50 units of NPH insulin, transitions to 35 units (70% of the NPH insulin total daily dose) or 40 units (80% of the NPH insulin total daily dose) of Abasaglar once daily

an intermediate- or long-acting insulin other than Lantus

Abasaglar

may differ from the prior basal insulin dose and other concomitant antihyperglycemic medications may need to be adjusted.

Abbreviations: Abasaglar  = Abasaglar® (insulin glargine) 100 units/mL; Lantus = Lantus® (insulin glargine) 100 units/mL; Toujeo = Toujeo® (insulin glargine) 300 units/mL.

References

1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: 22 August 2022


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request